EGFR and neoplasm: In addition, tumor hypoxia, generated by blocking angiogenesis, activates resistance to additional target receptors, such as epidermal growth factor receptor (EGFR) inhibitors [141] in non-small cell lung cancer and in a pancreatic cancer model [140].